Announced Date: 2023-12-20 (December 20, 2023)
Asset Name: HS-20093
Licensor: Hansoh Pharma (Hansoh) (China)
Licensee (Buyer): GSK plc （UK）
.
Asset Modality: Antibody-drug conjugate (ADC)
Asset Target: B7-H3 ，topoisomerase inhibitor (TOPOi) payload
Potential indication：Lung cancer, solid tumour
Current Stage: phase I and II trials in China
Scope of Authority:
GSK will obtain exclusive worldwide rights (excluding China’s mainland, Hong Kong, Macau, and Taiwan) to progress clinical development and commercialisation of HS-20093.
.
Deal Detail:
Upfront payment of $185 million;
Milestone payments up to $1.525 billion;
Total up to $1.71 billion.
Additional royalties based on net sales in the licensed territories.
.
Link:
GSK enters exclusive license agreement with Hansoh for HS-20093
